Why R&D must digitalize and become data-centric
Find out from Biogen, Beam Therapeutics and GlaxoSmithKline why digital transformation and the cloud are essential for R&D companies
Add bookmark
Biopharma R&D has changed dramatically in the last decade. The global Covid-19 pandemic in particular has awoken pharma and biotech companies to the need to work together with shared, high-quality data.
Becoming data-centric is now essential for modern R&D organizations to remain competitive. Today, scientists want – and should expect – to use the latest software designed for the modern approach to discovery and development.
This new, modern approach should be data-driven, easy to use, interoperable, designed for collaboration and capable of evolving over time, capturing the unique characteristics of an increasingly complex environment.
This exclusive Pharma IQ report, produced in association with Benchling, shares the experiences of industry professionals who have adopted cloud solutions to increase productivity, access shared intelligence and continue innovating at the pace of modern science.
Featuring case studies and commentary from Biogen, Beam Therapeutics and GlaxoSmithKline, it highlights how digital transformation has allowed them to eliminate manual processes and embrace automation to drive effective change management within their organizations.
Download this report to find out:
- Why digital transformation is essential
- The benefits provided by cutting-edge cloud technology
- The stories of biopharma companies successfully working in the cloud
